Three Pharmas Highlight Contrasting Approaches To Product Innovation

t will be interesting to see (1) if Regeneron’s investment in basic science yields the bumper crop of novel medications Yancopoulos clearly anticipates; (2) if Allergan continues to prove as adept in identifying, acquiring, and developing truly innovative early-stage compounds as company leadership believes it will be; and (3) if Teva’s plan to use emerging technologies to create compelling solutions around existing drugs proves a viable strategy.